US2013053318A1PendingUtilityA1

Modulating aquaporins with relaxin

43
Assignee: LAURA PARRYPriority: Mar 10, 2010Filed: Mar 10, 2011Published: Feb 28, 2013
Est. expiryMar 10, 2030(~3.6 yrs left)· nominal 20-yr term from priority
Inventors:Parry LauraKirk P. Conrad
A61P 7/10A61P 7/12A61P 13/12C12Q 1/6851G01N 33/6893A61K 38/2221A61P 15/04
43
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present disclosure relates to methods of modulating aquaporin channels. Particularly, the disclosure provides methods of modulating aquaporin channels in a tissue of a mammal by administering relaxin.

Claims

exact text as granted — not AI-modified
1 . A method of modulating an aquaporin channel in a mammal, comprising administering relaxin in an amount effective to modify aquaporin expression in a tissue of the mammal. 
     
     
         2 . The method of  claim 1 , wherein aquaporin expression is aquaporin gene expression. 
     
     
         3 . The method of  claim 2 , wherein aquaporin gene expression is up-regulated. 
     
     
         4 . The method of  claim 2 , wherein aquaporin gene expression is down-regulated. 
     
     
         5 . The method of  claim 1 , wherein aquaporin expression is aquaporin protein expression. 
     
     
         6 . The method of  claim 5 , wherein aquaporin protein expression is up-regulated. 
     
     
         7 . The method of  claim 5 , wherein aquaporin protein expression is down-regulated. 
     
     
         8 . The method of  claim 1 , wherein the aquaporin channel is selected from the group consisting of aquaporin-0 (AQP0), aquaporin-1 (AQP1), aquaporin-2 (AQP2), aquaporin-3 (AQP3), aquaporin-4 (AQP4), aquaporin-5 (AQP5), aquaporin-6 (AQP6), aquaporin-7 (AQP7), aquaporin-8 (AQP8), aquaporin-9 (AQP9) and aquaporin-10 (AQP10). 
     
     
         9 . The method of  claim 8 , wherein the aquaporin channel is selected from the group consisting of aquaporin-1 (AQP1), aquaporin-2 (AQP2), aquaporin-3 (AQP3), aquaporin-4 (AQP4), and aquaporin-5 (AQP5). 
     
     
         10 . The method of  claim 9 , wherein AQP3 is up-regulated in the cervix. 
     
     
         11 . The method of  claim 9 , wherein AQP5 is down-regulated in the cervix. 
     
     
         12 . The method of  claim 9 , wherein AQP2 is up-regulated in the kidney. 
     
     
         13 . The method of  claim 9 , wherein AQP4 is up-regulated in the kidney. 
     
     
         14 . The method of  claim 1 , wherein the tissue is selected from the group consisting of organ tissue, muscle tissue, epithelial tissue and endothelial tissue. 
     
     
         15 . The method of  claim 14 , wherein the organ tissue is selected from the group consisting of brain tissue, kidney tissue, lung tissue, and reproductive tissue. 
     
     
         16 . The method of  claim 1 , wherein the mammal is a human. 
     
     
         17 . A method of modulating an aquaporin channel in a mammal comprising administering relaxin. 
     
     
         18 . The method of  claim 17 , wherein relaxin modulates aquaporin gene expression. 
     
     
         19 . The method of  claim 17 , wherein relaxin modulates aquaporin protein expression. 
     
     
         20 . The method of  claim 17 , wherein the aquaporin is selected from the group consisting of aquaporin-1 (AQP1), aquaporin-2 (AQP2), aquaporin-3 (AQP3), aquaporin-4 (AQP4), and aquaporin-5 (AQP5).

Join the waitlist — get patent alerts

Track US2013053318A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.